Then, SEMA3B was secreted into the tumor microenvironment and competitively bound to the NRP1 receptor on vascular endothelial cells with VEGF to suppress the VEGF signaling pathway activation and to ultimately suppress tumor angiogenesis. This evidence concerns the gene SEMA3B and neoplasm.